SCHEMBL3322875

SCHEMBL3322875

Cc1c[nH]c(C(C)C)n1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3320859 0.78
SCHEMBL672624 0.76
SCHEMBL786437 0.75 NOS3 (0.31)
SCHEMBL11445039 0.74
SCHEMBL18595029 0.73
Hydrochloric Acid SCHEMBL28150542 0.73 NOS3 (0.30)
Ammonia Solution, Strong SCHEMBL28135320 0.73 NOS3 (0.30)
SCHEMBL13034847 0.73
SCHEMBL4616815 0.73
SCHEMBL28079964 0.73 NOS3 (0.30)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 182 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112250837-B Bio-based furan epoxy resin and method for preparing bio-based furan epoxy resin by thermal curing of solvent-free anhydride 南京先进生物材料与过程装备研究院有限公司 2023-05-05 CN claimed
CN-112250837-A Bio-based furan epoxy resin and method for preparing bio-based furan epoxy resin through solvent-free anhydride thermosetting 南京先进生物材料与过程装备研究院有限公司 2021-01-22 CN claimed
WO-2024092116-A1 COMBINATION OF TEAD INHIBITORS AND EGFR INHIBITORS AND USES THEREOF Ikena Oncology, Inc. (US) 2024-05-02 WO disclosed
US-20240018156-A1 SPIROCYCLIC COMPOUNDS C4 THERAPEUTICS, INC. (US) 2024-01-18 US disclosed
US-20230382891-A1 GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE (QPCTL) PROTEIN INHIBITORS AND USES THEREOF BLACKSMITH MEDICINES, INC. 2023-11-30 US disclosed
EP-4037772-B1 INDAZOLE CARBOXAMIDES AS KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2023-11-22 EP disclosed
US-20230357180-A1 DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2023-11-09 US disclosed
US-20230331737-A1 MTORC1 MODULATORS AND USES THEREOF AEOVIAN PHARMACEUTICALS, INC. 2023-10-19 US disclosed
WO-2023196975-A1 COMPOUNDS THAT INTERACT WITH RAS SUPERFAMILY PROTEINS FOR TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE SHY THERAPEUTICS, LLC (US) 2023-10-12 WO disclosed
US-11760728-B2 Tead inhibitors and uses thereof Ikena Oncology, Inc. (US) 2023-09-19 US disclosed
US-20230271935-A1 IRE1 SMALL MOLECULE INHIBITORS CORNELL UNIVERSITY 2023-08-31 US disclosed
US-20080280871-A1 5-Phenyl-4-Methyl-Thiazol-2-Yl-Amine Derivatives as Inhibitors of Phosphatidylin Ositol 3 Kinase Enzymes (PI13) For Treatment of Inflammatory Diseases NOVARTIS AG (CH) 2008-11-13 US disclosed
US-20080182838-A1 Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase MERCK CANADA INC. (CA) 2008-07-31 US disclosed
US-20080132542-A1 Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase MERCK CANADA INC. (CA) 2008-06-05 US disclosed
US-7361654-B2 Substituted heteroaryl amide modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof BRISTOL-MYERS SQUIBB CO. (US) 2008-04-22 US disclosed
US-20080027064-A1 Pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them ELBION GMBH (DE) 2008-01-31 US disclosed
WO-2007137820-A1 PYRIDO[3,2-e]PYRAZINES, THEIR USE AS INHIBITORS OF PHOSPHODIESTERASE 10, AND PROCESSES FOR PREPARING THEM ELBION GMBH (DE) 2007-12-06 WO disclosed
US-20070238694-A1 Purine compounds and methods of use thereof INOTEK PHARMACEUTICALS CORPORATION (US) 2007-10-11 US disclosed
US-20070049603-A1 Raf inhibitor compounds and methods of use thereof ARRAY BIOPHARMA INC. 2007-03-01 US disclosed
US-4056108-A IMIDAZOLE OR BENZIMIDAZOLE, FLAVOR ENHANCERS R. J. REYNOLDS TOBACCO COMPANY (US) 1977-11-01 US disclosed